In summary, obicetrapib, alone or combined with ezetimibe, lowers non-HDL cholesterol by enhancing LDL receptor-mediated VLDL clearance, thereby synergistically reducing atherosclerosis progression, while triple treatment with atorvastatin induces regression of established atherosclerotic lesions. Here, LDLR is linked to atherosclerosis.